201 related articles for article (PubMed ID: 18074436)
21. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
Wiegel T; Bottke D; Steiner U; Siegmann A; Golz R; Störkel S; Willich N; Semjonow A; Souchon R; Stöckle M; Rübe C; Weissbach L; Althaus P; Rebmann U; Kälble T; Feldmann HJ; Wirth M; Hinke A; Hinkelbein W; Miller K
J Clin Oncol; 2009 Jun; 27(18):2924-30. PubMed ID: 19433689
[TBL] [Abstract][Full Text] [Related]
22. Retrospective comparison of external beam radiotherapy and radical prostatectomy in high-risk, clinically localized prostate cancer.
Arcangeli G; Strigari L; Arcangeli S; Petrongari MG; Saracino B; Gomellini S; Papalia R; Simone G; De Carli P; Gallucci M
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):975-82. PubMed ID: 19395188
[TBL] [Abstract][Full Text] [Related]
23. [Practice guideline 'Prostate cancer: diagnosis and treatment'].
de Reijke TM; Battermann JJ; van Moorselaar RJ; de Jong IJ; Visser AP; Burgers JS
Ned Tijdschr Geneeskd; 2008 Aug; 152(32):1771-5. PubMed ID: 18754308
[TBL] [Abstract][Full Text] [Related]
24. Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy?
Pai HH; Eldridge B; Bishop D; Alexander A; Lesperance M; Blood P; Lim J; Ludgate C
Can J Urol; 2009 Apr; 16(2):4541-52. PubMed ID: 19364426
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse.
Choo R; Danjoux C; Gardner S; Morton G; Szumacher E; Loblaw DA; Cheung P; Pearse M
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):983-9. PubMed ID: 19409726
[TBL] [Abstract][Full Text] [Related]
26. Quality of life for men with prostate cancer.
Katz A
Cancer Nurs; 2007; 30(4):302-8. PubMed ID: 17666980
[TBL] [Abstract][Full Text] [Related]
27. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
Chung CS; Chen MH; Cullen J; McLeod D; Carroll P; D'Amico AV
Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
[TBL] [Abstract][Full Text] [Related]
28. Editorial comment on: Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial.
Korfage IJ
Eur Urol; 2009 Feb; 55(2):432. PubMed ID: 18783875
[No Abstract] [Full Text] [Related]
29. Prostate cancer (non-metastatic).
Wilt T
Clin Evid; 2003 Dec; (10):1023-38. PubMed ID: 15555136
[No Abstract] [Full Text] [Related]
30. Prostate cancer (non-metastatic).
Wilt T
Clin Evid; 2003 Jun; (9):973-85. PubMed ID: 12967402
[No Abstract] [Full Text] [Related]
31. Conventional treatments of localized prostate cancer.
Zerbib M; Zelefsky MJ; Higano CS; Carroll PR
Urology; 2008 Dec; 72(6 Suppl):S25-35. PubMed ID: 19095125
[TBL] [Abstract][Full Text] [Related]
32. [LHRH agonists in prostate cancer].
Rossi D; Cornu JN; Rouprêt M
Prog Urol; 2007 Apr; 17(2 Suppl 1):287-90. PubMed ID: 17569272
[No Abstract] [Full Text] [Related]
33. Effect of BMI on primary treatment of prostate cancer.
Davies BJ; Walsh TJ; Ross PL; Knight SJ; Sadetsky N; Carroll PR; Kane CJ
Urology; 2008 Aug; 72(2):406-11. PubMed ID: 18267336
[TBL] [Abstract][Full Text] [Related]
34. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02.
Rosenthal SA; Bae K; Pienta KJ; Sobczak ML; Asbell SO; Rajan R; Kerlin KJ; Michalski JM; Sandler HM;
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):672-8. PubMed ID: 18990504
[TBL] [Abstract][Full Text] [Related]
35. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
Palma D; Tyldesley S; Pickles T;
Cancer; 2008 May; 112(9):1941-8. PubMed ID: 18338814
[TBL] [Abstract][Full Text] [Related]
36. [GnRH analogues in the treatment of prostate cancer].
Zerbib M
Rev Prat; 2005; Spec. No():35-41. PubMed ID: 15822870
[No Abstract] [Full Text] [Related]
37. Antiandrogen therapy and side effects following radical prostatectomy.
Clin J Oncol Nurs; 2000; 4(4):179-80. PubMed ID: 11261099
[No Abstract] [Full Text] [Related]
38. Health related quality of life in patients treated with multimodal therapy for prostate cancer.
Wu AK; Cooperberg MR; Sadetsky N; Carroll PR
J Urol; 2008 Dec; 180(6):2415-22; discussion 2422. PubMed ID: 18930279
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic evaluation of PSA recurrence and review of hormonal management after radical prostatectomy.
Van Poppel H; Joniau S; Van Cleynenbreugel B; Mottaghy FM; Oyen R
Prostate Cancer Prostatic Dis; 2009; 12(2):116-23. PubMed ID: 19238169
[TBL] [Abstract][Full Text] [Related]
40. [Quality of life among patients with advanced prostate cancer: a survey using functional assessment of cancer therapy-prostate in China].
Zhang K; Gong K; Zhou LQ; Na YQ
Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(10):665-8. PubMed ID: 18642765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
